Lupin is currently trading at Rs. 879.50, up by 8.60 points or 0.99% from its previous closing of Rs. 870.90 on the BSE.
The scrip opened at Rs. 880.00 and has touched a high and low of Rs. 883.35 and Rs. 876.15 respectively. So far 15222 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 919.00 on 26-May-2020 and a 52 week low of Rs. 505.00 on 13-Mar-2020.
Last one week high and low of the scrip stood at Rs. 908.85 and Rs. 840.40 respectively. The current market cap of the company is Rs. 39457.00 crore.
The promoters holding in the company stood at 46.92%, while Institutions and Non-Institutions held 39.23% and 13.85% respectively.
Lupin has received approval for its Meloxicam Capsules, 5 mg and 10 mg, from the United States Food and Drug Administration (USFDA), to market a generic equivalent of Vivlodex Capsules, 5 mg and 10 mg, of Zyla Life Sciences US, Inc. The product would be manufactured at company’s Aurangabad facility, India, and is expected to be launched shortly.
Meloxicam Capsules, 5 mg and 10 mg, are indicated for management of osteoarthritis (OA) pain. Meloxicam Capsules (RLD: Vivlodex) had an annual sales of approximately $14 million in the US (IQVIA MAT March 2020).
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.